Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
IPCA LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 1,149.70 INR | +1.48% | +5.30% | +36.37% | |
| Nov. 22 | Interim dividend | FA |
| Nov. 10 | Transcript : Ipca Laboratories Limited, Q2 2024 Earnings Call, Nov 10, 2023 | CI |
| Sales 2024 * | 75.97 B 912 M | Sales 2025 * | 88.13 B 1,058 M | Capitalization | 292 B 3,502 M |
|---|---|---|---|---|---|
| Net income 2024 * | 7,007 M 84.13 M | Net income 2025 * | 9,907 M 119 M | EV / Sales 2024 * | 3,74x |
| Net cash position 2024 * | 7,681 M 92.22 M | Net cash position 2025 * | 11.78 B 141 M | EV / Sales 2025 * | 3,18x |
| P/E ratio 2024 * | 41,3x | P/E ratio 2025 * | 29,8x | Employees | 16,167 |
| Yield 2024 * | 0,49% | Yield 2025 * | 0,54% | Free-Float | 53.38% |
More Fundamentals
* Assessed data
More news
More recommendations
| 1 day | +1.48% | ||
| 1 week | +5.30% | ||
| Current month | +1.48% | ||
| 1 month | +17.88% | ||
| 3 months | +32.64% | ||
| 6 months | +60.98% | ||
| Current year | +36.37% |
1 week
1 092.05
1 153.00
1 month
971.001 153.00
Current year
669.801 153.00
1 year
669.801 153.00
3 years
669.801 383.10
5 years
358.501 383.10
10 years
200.001 383.10
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 67 | 1980 | |
Pranay Godha
CEO | Chief Executive Officer | 50 | 2003 |
| Chairman | 76 | 1975 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 76 | 1975 | |
| Director/Board Member | 75 | 2011 | |
Pranay Godha
CEO | Chief Executive Officer | 50 | 2003 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.53% | 443 M€ | -.--% | - | |
| 0.34% | 25 M€ | +10.15% | ||
| 0.19% | 40 M€ | +3.50% | - | |
| 0.17% | 6 M€ | +6.07% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-01 | 1,149.70 | +1.48% | 304,454 |
| 23-11-30 | 1,132.95 | +1.08% | 298,026 |
| 23-11-29 | 1,120.85 | +2.11% | 414,405 |
| 23-11-28 | 1,097.65 | +0.54% | 559,276 |
| 23-11-24 | 1,091.80 | +2.39% | 241,174 |
Delayed Quote NSE India Stock Exchange, December 01, 2023 at 06:43 am EST
More quotes
Ipca Laboratories Limited is an India-based pharmaceutical company. The Company is manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The Company offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The products of the Company are sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing APIâs and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd and Tonira Exports Limited.
Sector
Pharmaceuticals
Calendar
2024-02-12
- Q3 2024 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
C+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
1,149.70INR
Average target price
987.00INR
Spread / Average Target
-14.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +36.37% | 3 502 M $ | |
| +59.64% | 525 B $ | |
| +48.98% | 454 B $ | |
| -10.34% | 381 B $ | |
| -11.26% | 253 B $ | |
| -17.52% | 221 B $ | |
| +2.14% | 202 B $ | |
| -9.09% | 200 B $ | |
| -43.58% | 163 B $ | |
| +3.74% | 146 B $ |
